Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal ...

Ongoing Phase 1 and Phase 2 clinical programs continue to exhibit long-term durable remissions in hard-to-treat cancers, including glioblastoma (GBM) and 100% of treated Acute Myeloid Leukemia (AML) ...

Reports as of December 31 the company had cash of $11.1M as of December 31, compared with $21.3M as of December 31, 2023. Subsequently, in ...

Signs of all sorts dotted the crowd at Paepcke Park Saturday, March 8 at a rally organized by Carbondale resident Linda ...

Rep. Jeff Hurd, the Republican representing Colorado’s 3rd Congressional District in the U.S. House of Representatives, ...

Although chimeric antigen receptor T-cell therapy has raised hopes for long-term remission in autoimmune disease, it has ...

Nasal anti-CD3 spray reduces traumatic brain injury in mice, a potential breakthrough for TBI treatment. Read now.

On Feb. 24, a meeting was scheduled in Dolores that a staffer, Southwest Regional Director Naomi Dobbs, planned to attend. According to Cameryn Cass (Herald, Feb. 26) Dobbs fled the scene after ...

Tiziana is seeking FDA clearance for a Phase 2 clinical trial testing the safety and efficacy of its foralumab nasal spray in ...

Amgen and CytomX Therapeutics have kicked a phase 1 T-cell engager to the curb, axing the asset after assessing the clinical ...

Nasal anti-CD3 monoclonal antibody ameliorates traumatic brain injury, enhances microglial phagocytosis and reduces neuroinflammation via IL-10-dependent T reg –microglia crosstalk Nasal anti ...